Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant crossover study for cough in idiopathic pulmonary fibrosis
ISRCTN12372820Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of orvepitant in chronic cough and idiopathic pulmonary fibrosis (IPF) (4 cohorts), sponsored by NeRRe Therapeutics. Primary endpoint: IPF Coughing Severity Scale weekly average at Week 4. Started Mar 2022; status: completed.
02
Drugs
orvepitant
03
Conditions
chronic coughidiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ISRCTN12372820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12372820.